Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug 5;50(31):4459-4462.
doi: 10.1016/j.tetlet.2009.05.061.

An amine-derivatized, DOTA-loaded polymeric support for Fmoc Solid Phase Peptide Synthesis

Affiliations

An amine-derivatized, DOTA-loaded polymeric support for Fmoc Solid Phase Peptide Synthesis

Byunghee Yoo et al. Tetrahedron Lett. .

Abstract

An amine-derivatized DOTA has been used to modify the surface of a polymeric support for conventional Solid Phase Peptide Synthesis (SPPS) following standard Fmoc chemistry methods. This methodology was used to synthesize a peptide-DOTA conjugate that was demonstrated to be a PARACEST MRI contrast agent. Therefore, this synthesis methodology can facilitate Fmoc SPPS of molecular imaging contrast agents.

PubMed Disclaimer

Figures

Figure 1
Figure 1
NMR spectra of Hα in compounds 3∼6. The peak from Hα is marked with an arrow.
Figure 2
Figure 2
Detection of urokinase Plasminogen Activator (uPA) with 8. A) The proposed mechanism of uPA cleavage of 8 and the PARACEST spectra of 8 shows that an amide proton (red) is converted to an amine (blue) after uPA cleaves the ZGGR peptide ligand from the agent. B) The CEST spectrum showed a CEST effect from the amide at -52 ppm before uPA was added (red). The disappearance of this CEST effect after uPA was added (blue) was used to detect uPA. An enzyme-unresponsive agent, Yb-DOTA-Gly, shows a CEST effect at -16 ppm before and after uPA was added, which served as an internal control.
Scheme 1
Scheme 1
Synthesis of α-amino-DOTA and a peptide-DOTA PARACEST MRI contrast agent. (a) tert-butylbromoacetate, K2CO3 (6 eq.), acetonitrile, 70°C, 6 hrs, 83%; (b) CBZ-Gly(Br)-OMe, K2CO3 (6eq.), acetonitrile, 70 °C, 6 hrs, 83%; (c) H2, 10-Pd/C, ethanol; 2 hrs, quantitative; (d) Fmoc-Cl, zinc dust, acetonitrile, 87%; (e) 50% TFA in CH2Cl2, quantitative; (f) (i) Wang resin, HBTU (4 eq.), HOBt (1 eq.), DIEA (10 eq.), NMP, rt, overnight; (ii) 50% tert-BuOH in CH2Cl2, 70%; (g) (i) 20% piperidine, NMP; (ii) SPPS of Z-Gly-Gly-Arg(pbf) following standard Fmoc-chemistry (iii) 95% TFA, CH2Cl2, 4 hrs; (iv) Tm-triflate, acetonitrile, 50 °C, overnight.

Similar articles

Cited by

References

    1. Massoudand TF, Gambhir SS. Genes Dev. 2003;17:545. - PubMed
    1. De Leon-Rodriquez LM, Ortiz A, Weiner AL, Zhang S, Kovacs Z, Kodadek T, Sherry AD. J Am Chem Soc. 2002;124:3514. - PubMed
    1. Tung CH. Biopolymers (Pept Sci) 2004;76:391. - PubMed
    1. Knight LC. Handbook of Radiopharmaceuticals: Radiochemistry and Applications. John Wiley and Sons; New York: 2003. pp. 643–684.
    1. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. Mol Pharmaceutics. 2007;4:631. - PubMed

LinkOut - more resources